|
It is not known. There is no clear evidence that a second depo- medroxyprogesterone acetate (DMPA) injection (given 4 to 12 weeks after the first injection) offers measurable benefits for controlling heavy bleeding, but the existing studies are inadequate to address the question.
|
One study found a decrease in the number of days of bleeding and/or spotting in women immediately following each re-injection every 12 weeks.
Another study found no significant difference in the bleeding patterns of adolescents re-injected at 6 weeks compared to those re-injected at 12 weeks.
However, there were several limitations to the studies and more research is needed.
- WHO Special Programme of Research, Development and Research Training in Human Reproduction. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final Report. Contraception 1983;28(1):1-21.
- Harel Z, Biro FM, Kollar LM. Depo Provera in adolescents: effects of early second injection or prior oral contraception. Journal of Adolescent Health 1995;16:379-84.
|
